KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Receivables (2016 - 2025)

Pacira BioSciences has reported Change in Receivables over the past 16 years, most recently at $8.8 million for Q4 2025.

  • Quarterly results put Change in Receivables at $8.8 million for Q4 2025, down 30.45% from a year ago — trailing twelve months through Dec 2025 was $10.7 million (up 38.64% YoY), and the annual figure for FY2025 was $10.7 million, up 38.64%.
  • Change in Receivables for Q4 2025 was $8.8 million at Pacira BioSciences, up from $897000.0 in the prior quarter.
  • Over the last five years, Change in Receivables for PCRX hit a ceiling of $15.8 million in Q2 2021 and a floor of -$18.4 million in Q3 2021.
  • Median Change in Receivables over the past 5 years was $1.6 million (2022), compared with a mean of $1.9 million.
  • Biggest five-year swings in Change in Receivables: plummeted 962.6% in 2021 and later surged 688.68% in 2023.
  • Pacira BioSciences' Change in Receivables stood at $13.5 million in 2021, then plummeted by 63.52% to $4.9 million in 2022, then surged by 74.56% to $8.6 million in 2023, then skyrocketed by 47.12% to $12.7 million in 2024, then plummeted by 30.45% to $8.8 million in 2025.
  • The last three reported values for Change in Receivables were $8.8 million (Q4 2025), $897000.0 (Q3 2025), and $9.6 million (Q2 2025) per Business Quant data.